• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文会议>International Conference on Information Technology in Medicine and Education >Vorinostat Enhance TRAIL-Induced Apoptosis Via DR5 in Anaplastic Thyroid Cancer Cells
【24h】

Vorinostat Enhance TRAIL-Induced Apoptosis Via DR5 in Anaplastic Thyroid Cancer Cells

机译：伏立诺他通过DR5增强间变性甲状腺癌细胞中TRAIL诱导的凋亡。

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Anaplastic thyroid carcinoma (ATC) is one of the most aggressive human malignancies, which is refractory to surgery, radiotherapy, radioiodine therapy and conventional chemotherapy. Vorinostat (SAHA, also called suberoylanilide hydroxamic acid) is one of Histone deacetylase inhibitors (HDACIs), which is a promising agent for cancer therapy. Death receptor 5 (DR5) is a transmembrane receptor containing death domain that triggers cell death upon binding to TRAIL (tumor necrosis factor-related apoptosis-inducing ligand), and the combination of TRAIL and agents that increase the expression of DR5 is expected as a novel anticancer therapeutic strategy. Here we report that Vorinostat enhanced TRAIL-induced apoptosis in human anaplastic thyroid cancer cells. This effect is to be achieved through increasing expression of DR5 on the cell surface. Our results provide novel options into the therapy of ATC. We hope that these results could contribute to the advancement of the knowledge of this rare and aggressive cancer.
机译：间变性甲状腺癌（ATC）是人类最具侵略性的恶性肿瘤之一，对手术，放疗，放射碘疗法和常规化学疗法均无能为力。伏立诺他（SAHA，也称为辛二酰苯胺基异羟肟酸）是组蛋白脱乙酰基酶抑制剂（HDACIs）之一，是一种有望用于癌症治疗的药物。死亡受体5（DR5）是一种含有死亡域的跨膜受体，该死亡域在与TRAIL（肿瘤坏死因子相关的凋亡诱导配体）结合后触发细胞死亡，并且预计TRAIL和增加DR5表达的药物的组合会导致死亡。新的抗癌治疗策略。在这里我们报告说，伏立诺他增强了人类变性甲状腺癌细胞中TRAIL诱导的细胞凋亡。该作用将通过增加DR5在细胞表面的表达来实现。我们的结果为ATC的治疗提供了新的选择。我们希望这些结果可以促进对这种罕见和侵袭性癌症的了解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号